Peter Hedera

ORCID: 0000-0003-2699-4085
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Neurological disorders and treatments
  • Parkinson's Disease Mechanisms and Treatments
  • Genetic Neurodegenerative Diseases
  • Neurological diseases and metabolism
  • Hereditary Neurological Disorders
  • Botulinum Toxin and Related Neurological Disorders
  • Trace Elements in Health
  • Neurogenetic and Muscular Disorders Research
  • Heavy Metal Exposure and Toxicity
  • Genetics and Neurodevelopmental Disorders
  • Stroke Rehabilitation and Recovery
  • Neuroscience and Neural Engineering
  • Glycogen Storage Diseases and Myoclonus
  • Epilepsy research and treatment
  • Neurological and metabolic disorders
  • Advanced MRI Techniques and Applications
  • Aluminum toxicity and tolerance in plants and animals
  • Cerebral Palsy and Movement Disorders
  • Neuroscience and Neuropharmacology Research
  • Functional Brain Connectivity Studies
  • Alzheimer's disease research and treatments
  • Cerebrovascular and genetic disorders
  • Metabolism and Genetic Disorders
  • Pharmacological Effects and Toxicity Studies
  • Neurology and Historical Studies

University of Louisville
2020-2025

University of Louisville Hospital
2024

American Academy of Neurology
2024

University of Vermont
2024

University College London
2024

Yale New Haven Hospital
2023

Rehabilitation Institute of Michigan
2022

Vanderbilt University Medical Center
2013-2022

Geriatric Research Education and Clinical Center
1997-2021

Vanderbilt University
2011-2020

Abstract We have measured the T 2 * signal response associated with cortical activation due to finger motion at 1.5 Tesla. Both thin slice 2D and 3D images show intensity changes which vary from 2% 32% depending on volunteer, echo time, thickness, in‐plane resolution. The largest change occurred for thinnest slices highest resolution (2 mm 3 ). This is consistent reducing partial volume effects a simple difference in phase between intravascular surrounding parenchyma. No inflow enhancement...

10.1002/mrm.1910300318 article EN Magnetic Resonance in Medicine 1993-09-01

To compare tetrathiomolybdate and trientine in treating patients with the neurologic presentation of Wilson disease for frequency worsening, adverse effects, degree recovery.A randomized, double-blind, controlled, 2-arm study 48 disease. Patients either received 500 mg hydrochloride 2 times per day or 20 3 meals between 8 weeks. All 50 zinc day. were hospitalized weeks, speech function assessed weekly; discharged taking day, returned annually follow-up.A university hospital referral...

10.1001/archneur.63.4.521 article EN Archives of Neurology 2006-04-01

It is unclear what anticopper drug to use for patients with Wilson disease who present neurologic manifestations because penicillamine often makes them neurologically worse and zinc slow acting.To evaluate the frequency of worsening adverse effects ammonium tetrathiomolybdate.Open-label study 55 untreated (22 new) presenting treated tetrathiomolybdate varying from 120 410 mg/d 8 weeks then followed up 3 years. Neurologic function was assessed scored speech tests.A university hospital...

10.1001/archneur.60.3.379 article EN Archives of Neurology 2003-03-01

Therapy of Wilson's disease continues to evolve. In 1997, zinc acetate was added the list drugs approved by Food and Drug Administration, which includes penicillamine trientine. The mechanism zinc's anticopper action is unique. It induces intestinal cell metallothionein, binds copper prevents its transfer into blood. As cells die slough, contained eliminated in stool. Thus, absorption copper. universally agreed that pregnant patients should remain on therapy during pregnancy. There are...

10.1002/hep.510310216 article EN Hepatology 2000-02-01

WE used immunocytochemical methods to define abnormalities in the cerebral endothelium and vascular basement membrane patients with Alzheimer's disease (AD) aging control subjects. Double immunostaining antibodies endothelial cell markers CD34 CD31 revealed an absence of staining many capillary profiles that still appeared retain their membranes stained by collagen IV. Such differential labeling, clearly suggesting capillaries collapsed or degenerated endothelium, was frequently (> 90%...

10.1097/00001756-199502000-00018 article EN Neuroreport 1995-02-01

To report 5-year outcomes from the subthalamic nucleus (STN) deep brain stimulation (DBS) in early-stage Parkinson disease (PD) pilot clinical trial.

10.1212/wnl.0000000000009946 article EN Neurology 2020-06-30

Abstract Background and Purpose Clinically, Parkinson's disease ( PD ) presents with asymmetric motor symptoms. The left nigrostriatal system appears more susceptible to early degeneration than the right, a left‐lateralized pattern of neuropathological changes is also described in several neurodegenerative conditions, including Alzheimer's disease, frontotemporal dementia, Huntington's disease. In this study, we evaluated hemispheric differences estimated rates atrophy large,...

10.1002/brb3.573 article EN cc-by Brain and Behavior 2016-10-06
Erin Furr Stimming Daniel O. Claassen Elise Kayson Jody Goldstein Raja Mehanna and 93 more Hui Zhang Grace Liang Dietrich Haubenberger Jamie Adams Christopher A. Beck Cheryl Chen Martha Nance Claudia Testa Patricia Huffman Amy M. Chesire Frederick J. Marshall Praveen Dayalu Angela Stovall Deborah A. Hall Jacob Hawkins Letty Ginsburg Henry Moore Tiago Mestre Tanya Thompson Natalie K. Connors H. Diana Rosas Allison M. Daley Sandra K. Kostyk Casey Mitchell Amy Hellman Sheryl Houston Danielle Buchanan Katherine E. McDonell Stewart A. Factor Elaine Sperin Andrea Hurt Joanne Wojcieszek Mike Adurogbangba Lynn A. Raymond Jody Corey‐Bloom Chase Snell Courtney Blair Victor Sung Sophia Antonioli Jacqueline Fung Simon Laganiere Luis Sierra William Mallonee Greg Suter Danny Bega Zsa Zsa Brown Lawrence Elmer Nancy Vollmar Debra del Castillo Yihan Lin Kelly L. Andrzejewski Patricia Weigel Trevor Hawkins Kendra Kirby Cimmaron Retzik-Stahr Lauren Seeberger Rohit Dhall Anja Rassmann McKenzie Luxmore B.L. Scott Bisena Bulica James T. Boyd K. Chan Nikolaus R. McFarland Kyle Rizer Patricia Conlon Valerie Suski Federico Rodríguez‐Porcel Sandra R. Wilson Christine Farrell David J. Hunter David Houghton Sarah Seoane Clare Gibbons Philippe Rizek Robin Kuprewicz Steven Lo Miroslav Cuturic Vicki Segro Kate Greenly Fredy J. Revilla Enrique Urrea‐Mendoza Kevin J. Black Thomas L. Davis Natividad Stover Andrew P. Duker Jay Van Gerpen Peter Hedera William G. Ondo Karen E. Anderson Stephen Bradley Ying Kuen Cheung Samuel Frank

10.1016/s1474-4422(23)00127-8 article EN The Lancet Neurology 2023-05-18

ASPEN-1 was a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, duration of response, and safety 2 doses DaxibotulinumtoxinA for Injection (DAXI), novel botulinum toxin type A formulation in participants with cervical dystonia (CD).

10.1212/wnl.0000000000208091 article EN cc-by-nc-nd Neurology 2024-01-31

The subthalamic nucleus is thought to play a crucial role in controlling impulsive actions. Networked among the basal ganglia and receiving input from several cortical areas, well positioned influence action selection when faced with competing conflicting outcomes. purpose of this study was test dissociable roles dorsal ventral aspects during conflict patients Parkinson's disease undergoing intraoperative neurophysiological recording explore potential mechanism for inhibitory control. We...

10.1093/braincomms/fcaf021 article EN cc-by Brain Communications 2025-01-16

Abstract Recent emphasis on high resolution gradient echo studies in functional imaging has led to the conclusion that there are likely three domains of response blood circulation brain when considering field inhomogeneity effects venous pre‐ and during activation. The first is a coherent effect due large or macroscopic vessels order size voxel (ca 200–500 μm most studies). These can lead very signal changes (up 100%). second at venule level 50–200 μm) associated with smaller parenchymal...

10.1002/nbm.1940070109 article EN NMR in Biomedicine 1994-03-01

Our goal was to determine whether functional MRI on a standard 1.5 T system can localize activation during visual vigilance sustained attention task and this corresponds results described in PET investigation of similar task.Sixteen volunteers were studied using gradient echo technique. A single axial section oriented within stereotaxic coordinate space, 40 mm superior the anterior-posterior commissure line. Images with eyes closed followed by images subject concentration small dim spot....

10.1097/00004728-199609000-00002 article EN Journal of Computer Assisted Tomography 1996-09-01

A range of phenotypes including Greig cephalopolysyndactyly and Pallister-Hall syndromes (GCPS, PHS) are caused by pathogenic mutation the GLI3 gene. To characterize clinical variability mutations, we present a subset cohort 174 probands referred for analysis. Eighty-one with typical GCPS or PHS were previously reported, report remaining 93 here. This includes 19 (12 mutations) who fulfilled criteria PHS, 48 (16 features but did not meet (sub-GCPS sub-PHS), 21 (6 oral-facial-digital...

10.1002/humu.21328 article EN Human Mutation 2010-07-29

THAP1 encodes a transcription factor (THAP1) that harbors an atypical zinc finger domain and regulates cell proliferation. An exon 2 insertion/deletion frameshift mutation in is responsible for DYT6 dystonia Amish-Mennonites. Subsequent screening efforts familial, mainly early-onset, primary identified additional sequence variants non-Amish subjects.To examine large cohort of subjects with adult-onset THAP1.With high-resolution melting, all 3 exons were screened 1,114 dystonia, 96...

10.1212/wnl.0b013e3181ca00ca article EN Neurology 2010-01-18

To demonstrate single abobotulinumtoxinA injection efficacy in lower limb vs placebo for adults with chronic hemiparesis and assess long-term safety of repeated injections.In a multicenter, double-blind, randomized, placebo-controlled, single-cycle study followed by 1-year open-label, multiple-cycle extension, ≥6 months after stroke/brain injury received one (abobotulinumtoxinA 1,000 U, 1,500 placebo) ≤4 open-label cycles (1,000, U) at ≥12-week intervals. Efficacy measures included Modified...

10.1212/wnl.0000000000004687 article EN cc-by-nc-nd Neurology 2017-11-01

<h3>Objective</h3> To evaluate whether the progression of individual motor features was influenced by early deep brain stimulation (DBS), a post hoc analysis Unified Parkinson9s Disease Rating Scale–III (UPDRS-III) score (after 7-day washout) conducted from 2-year DBS in Parkinson disease (PD) pilot trial dataset. <h3>Methods</h3> The prospective enrolled patients with PD aged 50–75 years, treated medications for 6 months–4 and no history dyskinesia or other fluctuations, who were randomized...

10.1212/wnl.0000000000005903 article EN Neurology 2018-06-29
Coming Soon ...